Operationalizing Genomic Medicine

Laboratory Practice Considerations Beyond the Assay
  • Nikoletta Sidiropoulos
    Correspondence
    Corresponding author.
    Affiliations
    The Robert Larner, M.D. College of Medicine at The University of Vermont, Burlington, VT, USA

    Genomic Medicine, Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT 05401, USA
    Search for articles by this author
Published:September 02, 2021DOI:https://doi.org/10.1016/j.yamp.2021.07.006
      Clinical value of genomic testing is realized via investment in a laboratory professional that champions efforts comprising a genomic medicine service that supports the assay.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Advances in Molecular Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Genomics and medicine
        National Human Genome Research Institute website.
        (Available at:) ([Accessed April 3, 2021])
      1. Table of pharmacogenomic biomarkers in drug labeling. U.S. Food and Drug Administration website.
        (Available at:) ([Accessed April 3, 2021])
        • Ginsburg G.S.
        • Phillips K.A.
        Precision medicine: from science to value.
        Health Aff (Millwood). 2018; 37: 694-701
        • Sireci A.N.
        • Patel J.L.
        • Joseph L.
        • et al.
        Molecular pathology economics 101: an overview of molecular diagnostics coding, coverage, and reimbursement a report of the association for molecular pathology.
        J Mol Diagn. 2020; 22: 975-993
        • Hsiao S.J.
        • Mansukhani M.M.
        • Carter M.C.
        • et al.
        The history and impact of molecular coding changes on coverage and reimbursement of molecular diagnostic tests: transition from stacking codes to the current molecular code set including genomic sequencing procedures.
        J Mol Diagn. 2018; 20: 177-183
        • Wolf J.
        • Seto T.
        • Han J.
        • et al.
        Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer.
        N Engl J Med. 2020; 383: 944-957
      2. NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer, NCCN Evidence Blocks Version 4.2021. National Comprehensive Cancer Network website.
        (Available at:) ([Accessed April 4, 2021])
        • Awad M.
        Impaired c-Met receptor degradation mediated by MET exon 14 mutations in non-small-cell lung cancer.
        J Clin Oncol. 2016; 34: 879-881
        • Frampton G.M.
        • Ali S.M.
        • Rosenzweig M.
        • et al.
        Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
        Cancer Discov. 2015; 5: 850-859
        • Davies K.D.
        • Aprille L.
        • Lawrence C.A.
        • et al.
        DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer.
        J Thorac Oncol. 2019; 14: 737-741
        • Benayed R.
        • Offin M.
        • Mullaney K.
        • et al.
        High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden.
        Clin Cancer Res. 2019; 25: 4712-4722
        • Johnston K.M.
        • Sheffield B.S.
        • Yip S.
        • et al.
        Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact.
        Curr Oncol. 2020; 27: 569-577
        • Signorovitch J.
        • Zhou Z.
        • Ryan J.
        • et al.
        Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
        J Med Econ. 2019; 22: 140-150
      3. The personalized medicine report, 2020: opportunity, challenges, and the future. Personalized Medicine Coalition website.
        (Available at:) ([Accessed April 10, 2021])
        • Ascierto P.A.
        • Bifulco C.
        • Palmieri G.
        • et al.
        Preanalytic variables and tissue stewardship for reliable next-generation sequencing (NGS) clinical analysis.
        J Mol Diagn. 2019; 21: 756-767
        • Balla A.
        • Hampel K.J.
        • Sharma M.K.
        • et al.
        Comprehensive validation of cytology specimens for next-generation sequencing and clinical practice experience.
        J Mol Diagn. 2018; 20: 812-821
        • Clinical Informatics
        American Medical Informatics Association website.
        (Available at:) ([Accessed April 10, 2021])
        • Roy S.
        • LaFramboise W.A.
        • Nikiforov Y.E.
        • et al.
        Next-generation sequencing informatics: challenges and strategies for implementation in a clinical environment.
        Arch Pathol Lab Med. 2016; 140: 958-975
        • Sepulveda J.L.
        • Young D.S.
        The ideal laboratory information system.
        Arch Pathol Lab Med. 2013; 137: 1129-1140
        • Hurle B.
        • Citrin T.
        • Jenkins J.F.
        • et al.
        What does it mean to be genomically literate?: National Human Genome Research Institute Meeting Report.
        Genet Med. 2013; 15: 658-663
        • Bangash H.
        • Kullo I.J.
        Implementation science to increase adoption of genomic medicine: an urgent need.
        J Pers Med. 2021; 11: 19
        • National Research Council, Committee on A Framework for Developing a New Taxonomy of Disease
        Toward precision medicine: building a Knowledge Network for Biomedical research and a New Taxonomy of Disease.
        National Academies Press, Washington DC2011